Article Sidebar

Submitted
Apr 21, 2021
Published
Apr 21, 2021
Download
PDF
Statistic
Read Counter : 33 Download : 31

Main Article Content

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology characterised by inflammation and fibrosis of the biliary tree. The aim of this review is to find out the cause, symptoms, and treatment of PSC. Remissions and relapses characterize the disease course. PSC may remain quiescent for long periods of time in some patients, however, it is progressive. The mean age at diagnosis is 40 years and men are affected twice as often as women. There is a reported annual incidence of PSC of 0.9–1.31/100,000 and point prevalence of 8.5–13.6/100,000. In most, the disease progresses to cirrhosis and liver failure. Cholangiocarcinoma develops in 8–30% of patients. PSC is thought to be immune mediated and is often associated with inflammatory bowel disease, especially ulcerative colitis. The disease is diagnosed on typical cholangiographic and histological findings and after exclusion of secondary sclerosing cholangitis. Median survival has been estimated to be 12 years from diagnosis in symptomatic patients. Patients who are asymptomatic at diagnosis, the majority of whom will develop progressive disease, have a survival rate greater than 70% at 16 years after diagnosis. Liver transplantation remains the only effective therapeutic option for patients with end-stage liver disease from PSC, although high dose ursodeoxycholic acid may have a beneficial effect.

Keywords

Primary sclerosing cholangitis(PSC) Biliary tree Cholangiocarcinoma Inflammatory bowel disease Cholangiography Ursodeoxycholic acid

Article Details

How to Cite
K. Dilip Krishnan, Molly Mathew, Joel Johny, Dr. Raheeda T.A, Kripesh P, Alif Latheef, Fathimath Shamna R, & Swapna P. (2021). Primary sclerosing cholangitis- a comprehensive review and update. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(2), 194-205. https://doi.org/10.61096/ijrpp.v4.iss2.2015.194-205
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1] Pietro Invernizzi MD, Ian R Mackay MD, et al. Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol. 2008;14(21):3338-3349.
  2. [2] Chalermrat Bunchorntavakul, MD, Tawesak Tanwandee, Phunchai Charatcharoenwitthaya, et al. Primary Sclerosing Cholangitis: From Pathogenesis to Medical Management. North American Journal of Medicine and Science. 2012;5(2):82-92.
  3. [3] Roger W. Chapman, Frank Lammert, Ulrich Beuers, et al. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. European Association for the study of the liver. J Hepatol. 2009;237-267.
  4. [4] Dr. A.P. Krishna. Textbook of physiology, 4th edition, 2012;1:82-85.
  5. [5] T.J.Weismuller, Jochen Wedemeyer, Stefen Kubicka, et al. The challenges in primary sclerosing cholangitis-Aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008:S38-S57.
  6. [6] Roger Chapman, Johan Fevery, Anthony Kalloo, et al. AASLD practice guidelines-Diagnosis and Management of Primary Sclerosing Cholangitis. Hepatology. 2010;51(2):662-665.
  7. [7] JD Feuerstein, EB Tapper, et al. Primary sclerosing cholangitis: an update. OA Hepatology. 2013:1-6.
  8. [8] Christos Tsaitas, Anysia Semertzidou, Emmanouil Sinakos. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol. 2014;6(4):178.
  9. [9] Larusso, Benjamin L Shneider, Dennis Black, et al. Primary sclerosing cholangitis-summary of a workshop. Hepatology. 2006;44(3):753-54.
  10. [10] Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and Management. Gastroenterology. 2013;145(3):521-36.
  11. [11] Young-Mee Lee, Marshall M, Kaplan M.D, et al. Practice guidelines-Management of Primary Sclerosing Cholangitis. Am J Gastroenterol. 2002;97(3)
  12. [12] A Boudewijn de Vries, Marcel Janse, Hans Blokzijl, et al. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21(6): 1956-1971.
  13. [13] Germana V Geegorio, Bernard Portmann, John Karani, et al. Autoimmune Hepatitis/Sclerosing Cholangitis Overlap Syndrome in Childhood: A16-Year Prospective Study. Hepatology. 2001;33(3):544-553.
  14. [14] Tom H Karlsen and Kirsten Muri Boberg. Update on primary sclerosing cholangitis.
  15. [15] J Hepatol. 2013;59:571-582.
  16. [16] Khurana V, et al. Primary Sclerosing Cholangitis. Medscape. June 2012.
  17. [17] T.H.Karlsen, Erik Schrumpf, Kirsten M Boberg, et al. Update on primary sclerosing cholangitis. Digestive and Liver Disease. 2010:390-400.
  18. [18] Elisabeth Krones, Ivo Graziadei, Michael Trauner, et al. Evolving concepts in primary sclerosing cholangitis. Liver International. 2012:352-369.
  19. [19] Bergquist A, Lindberg, et al. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol. 2005;42(2):252-6.
  20. [20] F.D Mendes, K.D.Lindor MD. Primary sclerosing cholangitis. Clin Liver Dis 8. 2004:195-211.
  21. [21] Vierling JM. Animal models for primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001;15:591-610.
  22. [22] Joy Worthington and Roger Chapman. Primary sclerosing cholangitis. Orphanet Journal of Rare Diseases. 2006:1-7.
  23. [23] Paul Angulo and Keith D Lindor. Primary Sclerosing Cholangitis. Hepatology. 1999;30(1):325-332.
  24. [24] Terjung B, Muennich M, Gottwein J,et al. Identification of myeloid-specific tubulin-beta isotype 5 as target antigen of antineutrophil cytoplasmic antibodies in autoimmune liver disorders. Hepatology. 2005;42:288A
  25. [25] Bansi D, Fleming KA, Chapman R, et al. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis. Gut. 1996;38:384-389.
  26. [26] Grant AJ, Lalor PF, Hubscher SG, et al. MAdCAM-1 in chronic inflammatory liver disease. Hepatology. 2001;33:1065-1072.
  27. [27] Marina G, Silveira MD, Keith D Lindor MD, et al. Primary sclerosing cholangitis. Can J Gastroenterol. 2008;22(8):689-98.
  28. [28] Lee YM, Kaplan MM, et al. Primary sclerosing cholangitis. N Engl J Med. 1995;332(14):924-33.
  29. [29] Farrant JM, Hayllar KM, Karani J, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991;100:1710-1717.
  30. [30] Cullen SN, Chapman RW. Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005;21:933-948.
  31. [31] Schramm C, Schirmacher P, Gerker G, et al. Medical treatment for primary sclerosing cholangitis:Risk versus benefit. Hepatology. 2000:871-872.
  32. [32] Boberg KM, Egeland T, Schrumpf E, et al. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol. 2003;38:991-995.
  33. [33] Bjornsson E, Lindqvist-Ottosson J, Asztely M, et al. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:502-8.
  34. [34] Brandsaeter B, Isoniemi H, Broome U, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol. 2004;40:815-822.
  35. [35] Gordon F, et al. Recurrent primary sclerosing cholangitis. Clinical diagnosis and long term management issues. Liver Transpl. 2006;12:S73-S75.
  36. [36] Bjornsson E, Pasha TM, et al. The natural history of small duct primary sclerosing cholangitis. Gastroenterology. 2008;134(4):975-80.
  37. [37] Campsen J, Zimmerman MA, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation-a time course. Liver Transpl. 2008;14(2):181-5.